Dendritic cells: Making progress with tumour regression?

Due to their potent ability to activate the immune system, dendritic cells (DC) are showing promise as potential adjuvants for tumour immunotherapy of cancer patients. However, little is known about the effect tumour cells can have on DC function. Indeed, the discovery of different DC subsets with d...

Full description

Saved in:
Bibliographic Details
Published in:Immunology and cell biology 2002-12, Vol.80 (6), p.520-530
Main Authors: Byrne, Scott N, Halliday, Gary M
Format: Article
Language:English
Subjects:
Animals
Chemokines - metabolism
DC subsets
dendritic cells
Dendritic Cells - immunology
Humans
immunologic surveillance
immunotherapy
Killer Cells, Natural - immunology
Macrophages - immunology
Mice
Neoplasm Regression, Spontaneous - immunology
Neoplasms - immunology
T-Lymphocytes - immunology
tumour escape
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to their potent ability to activate the immune system, dendritic cells (DC) are showing promise as potential adjuvants for tumour immunotherapy of cancer patients. However, little is known about the effect tumour cells can have on DC function. Indeed, the discovery of different DC subsets with different immunological functions indicates that the relationship between tumour cells and tumour‐infiltrating DC subtypes is likely to be complex. There remains a lot to be understood about the effects of tumours on DC before we can expect to benefit from DC‐based tumour immunotherapy of cancer patients. Here we review the recent advances being made in understanding DC phenotype and function in relation to interactions with different types of tumours.
ISSN:0818-9641
1440-1711
DOI:10.1046/j.1440-1711.2002.01122.x